Okabe, Y. & Medzhitov, R. Tissue biology perspective on macrophages. Nat. Immunol. 17, 9–17 (2016).
Tauber, A. I. Metchnikoff and the phagocytosis theory. Nat. Rev. Mol. Cell Biol. 4, 897–901 (2003).
Lazarov, T., Juarez-Carreno, S., Cox, N. & Geissmann, F. Physiology and diseases of tissue-resident macrophages. Nature 618, 698–707 (2023).
Park, M. D., Silvin, A., Ginhoux, F. & Merad, M. Macrophages in health and disease. Cell 185, 4259–4279 (2022).
Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445–455 (2013).
Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946 (2012).
Cassetta, L. & Pollard, J. W. A timeline of tumour-associated macrophage biology. Nat. Rev. Cancer 23, 238–257 (2023).
Dawson, C. A. et al. Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling. Nat. Cell Biol. 22, 546–558 (2020).
Franklin, R. A. et al. The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014).
Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001).
Zhang, X. et al. Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature 619, 616–623 (2023). Together with Dawson et al. (2020) and Franklin et al. (2014), this work shows that macrophage development, maintenance and function are closely linked to diverse cell differentiation programmes. The expansion of macrophage populations is supported in both mammary gland physiology and cancer contexts, but is suppressed by MYC-expressing, epiblast-like cancer cell differentiation states.
Claveria, C., Giovinazzo, G., Sierra, R. & Torres, M. Myc-driven endogenous cell competition in the early mammalian embryo. Nature 500, 39–44 (2013).
Nirala, B. K. et al. MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma. JCI Insight 8, e164947 (2023).
Wu, X. et al. MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination. J. Immunother. Cancer 9, e001388 (2021).
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836–847 (2012).
Liou, G. Y. et al. Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov. 5, 52–63 (2015).
Liu, Y. et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat. Commun. 13, 2665 (2022).
Komarova, E. A. et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 19, 1030–1032 (2005).
Schwitalla, S. et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23, 93–106 (2013).
Nian, Z. et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation. Immunity 57, 2344–2361.e7 (2024).
Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572, 538–542 (2019).
Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657 (2019).
Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551 (2011).
Liang, H. et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun. 8, 1736 (2017).
Brown, G. D. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 6, 33–43 (2006).
Chiba, S. et al. Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. eLife 3, e04177 (2014).
Mattiola, I. et al. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis. Nat. Immunol. 20, 1012–1022 (2019).
Daley, D. et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat. Med. 23, 556–567 (2017).
Tang, C. et al. Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression. Nat. Commun. 14, 1493 (2023).
Li, M. O. et al. Multilayered immunity by tissue-resident lymphocytes in cancer. Ann. Rev. Immunol. 42, 647–677 (2024).
Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Ann. Rev. Immunol. 37, 173–200 (2019).
Elewaut, A. et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature 637, 716–725 (2025).
Park, M. D. et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792–801 (2023).
Nixon, B. G. et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 55, 2044–2058.e5 (2022).
Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell 40, 624–638.e9 (2022). Together with Elewaut et al. (2025) and Nixon et al. (2022), this work shows that monocytes and macrophages can cooperate with CD8⁺ T cells, driving them towards either cytotoxic states that promote antitumour activity or dysfunctional states that support pro-tumour functions.
Di Paolo, N. C. & Shayakhmetov, D. M. Interleukin 1α and the inflammatory process. Nat. Immunol. 17, 906–913 (2016).
Hanggi, K. et al. Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer Cell 42, 2015–2031.e11 (2024).
Watari, K. et al. Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. PLoS One 9, e99568 (2014).
Vande Walle, L. & Lamkanfi, M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat. Rev. Drug. Discov. 23, 43–66 (2024).
Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal. Transduct. Target. Ther. 8, 70 (2023).
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
Huber-Lang, M., Lambris, J. D. & Ward, P. A. Innate immune responses to trauma. Nat. Immunol. 19, 327–341 (2018).
Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986).
Koelwyn, G. J. et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nat. Med. 26, 1452–1458 (2020).
Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).
Buttigieg, M. M., Vlasschaert, C., Bick, A. G., Vanner, R. J. & Rauh, M. J. Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes. Cell Rep. Med. 6, 101989 (2025).
Park, M. D. et al. Hematopoietic aging promotes cancer by fueling IL-1α-driven emergency myelopoiesis. Science 386, eadn0327 (2024).
Hegde, S. et al. Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours. Nature 646, 1214–1222 (2025).
Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792–809.e723 (2021). This systematic, pan-cancer, single-cell transcriptomic analysis of tumour-associated macrophages across diverse human cancers reveals several conserved monocyte and macrophage programmes.
Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883–1900.e5 (2021).
Matusiak, M. et al. Spatially segregated macrophage populations predict distinct outcomes in colon cancer. Cancer Discov. 14, 1418–1439 (2024).
Caronni, N. et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415–422 (2023). This study describes the reciprocal interaction between inflammatory cancer cells and macrophages, whereby cancer cells release TNF, PGE2 and ATP to activate inflammasomes in macrophages and, in turn, macrophages secrete IL-1β to further stimulate cancer cells.
Deng, Q. et al. NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver. Cancer Lett. 442, 21–30 (2019).
Gu, H. et al. NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma. Transl. Lung Cancer Res. 11, 858–868 (2022).
Traughber, C. A. et al. Myeloid-cell-specific role of Gasdermin D in promoting lung cancer progression in mice. iScience 26, 106076 (2023).
Kuwano, T. et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18, 300–310 (2004).
Rius, J. et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807–811 (2008).
Vlaicu, P. et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 13, 197 (2013).
Chen, Y. et al. Tumor-associated monocytes promote mesenchymal transformation through EGFR signaling in glioma. Cell Rep. Med. 4, 101177 (2023).
Hoagland, D. A. et al. Macrophage-derived oncostatin M repairs the lung epithelial barrier during inflammatory damage. Science 389, 169–175 (2025).
Daley, D. et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J. Exp. Med. 214, 1711–1724 (2017).
Fabre, T. et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci. Immunol. 8, eadd8945 (2023).
De Ponti, F. F. et al. Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair. Immunity 58, 362–380.e10 (2025).
Wei, J. et al. Characterizing intercellular communication of pan-cancer reveals SPP1+ tumor-associated macrophage expanded in hypoxia and promoting cancer malignancy through single-cell RNA-seq data. Front. Cell Dev. Biol. 9, 749210 (2021).
Bill, R. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381, 515–524 (2023). This study reveals a dichotomy of tumour macrophage states across diverse human cancers, characterized by CXCL9⁺ or SPP1⁺ polarity, with CXCL9⁺ macrophages driven by interferon signalling and SPP1⁺ macrophages induced by hypoxic cues.
Weber, G. F. et al. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol. 72, 752–761 (2002).
Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342–356 (2014).
Ahmed, M. et al. An osteopontin/CD44 axis in RhoGDI2-mediated metastasis suppression. Cancer Cell 30, 432–443 (2016).
Sangaletti, S. et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74, 4706–4719 (2014).
Klement, J. D. et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J. Clin. Invest. 128, 5549–5560 (2018).
Dunsmore, G. et al. Timing and location dictate monocyte fate and their transition to tumor-associated macrophages. Sci. Immunol. 9, eadk3981 (2024).
Yan, H. et al. Hexokinase 2 senses fructose in tumor-associated macrophages to promote colorectal cancer growth. Cell Metab. 36, 2449–2467.e6 (2024).
Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744 (2000).
Du, R. et al. HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206–220 (2008).
Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686–698.e14 (2019).
Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34–45 (2019).
Kwart, D. et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 41, 111769 (2022).
Patterson, M. T. et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 42, 112732 (2023).
Farber, J. M. A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc. Natl Acad. Sci. USA 87, 5238–5242 (1990).
Qu, Y. et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 32, 107873 (2020).
House, I. G. et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin. Cancer Res. 26, 487–504 (2020).
Naigles, B., Narla, A. V., Soroczynski, J., Tsimring, L. S. & Hao, N. Quantifying dynamic pro-inflammatory gene expression and heterogeneity in single macrophage cells. J. Biol. Chem. 299, 105230 (2023).
House, I. G. et al. CRISPR–Cas9 screening identifies an IRF1–SOCS1-mediated negative feedback loop that limits CXCL9 expression and antitumor immunity. Cell Rep. 42, 113014 (2023).
Xiao, P. et al. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment. Oncogene 37, 5088–5100 (2018).
Pascual-Garcia, M. et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat. Commun. 10, 2416 (2019).
Freeman, P. et al. Inhibition of insulin-like growth factors increases production of CXCL9/10 by macrophages and fibroblasts and facilitates CD8+ cytotoxic T cell recruitment to pancreatic tumours. Front. Immunol. 15, 1382538 (2024).
Petty, A. J. et al. Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J. Clin. Invest. 129, 5151–5162 (2019).
Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643–1660.e17 (2020).
Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578–584 (2021).
Jiang, X. et al. Expression profiles of FABP4 and FABP5 in breast cancer: clinical implications and perspectives. Discov. Oncol. 16, 357 (2025).
Yorek, M. et al. FABP4-mediated lipid accumulation and lipolysis in tumor-associated macrophages promote breast cancer metastasis. eLife 13, RP101221 (2024).
Hao, J. et al. Circulating adipose fatty acid binding protein is a new link underlying obesity-associated breast/mammary tumor development. Cell Metab. 28, 689–705.e5 (2018).
Hao, J. et al. Expression of adipocyte/macrophage fatty acid-binding protein in tumor-associated macrophages promotes breast cancer progression. Cancer Res. 78, 2343–2355 (2018).
Tiwari, P. et al. Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer. J. Exp. Med. 216, 1345–1358 (2019).
Chakarov, S. et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science 363, eaau0964 (2019).
Moura Silva, H. et al. c-MAF-dependent perivascular macrophages regulate diet-induced metabolic syndrome. Sci. Immunol. 6, eabg7506 (2021).
Anstee, J. E. et al. LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer. Dev. Cell 58, 1548–1561.e10 (2023).
Opzoomer, J. W. et al. Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Sci. Adv. 7, eabg9518 (2021).
Elfstrum, A. K. et al. LYVE-1-expressing macrophages modulate the hyaluronan-containing extracellular matrix in the mammary stroma and contribute to mammary tumor growth. Cancer Res. Commun. 4, 1380–1397 (2024).
Muliaditan, T. et al. Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer. Clin. Cancer Res. 24, 1617–1628 (2018).
Nalio Ramos, R. et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell 185, 1189–1207.e25 (2022).
Zhu, Y. et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 323–338.e6 (2017).
Baer, J. M. et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Nat. Immunol. 24, 1443–1457 (2023).
Etzerodt, A. et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J. Exp. Med. 217, e20191869 (2020).
Zhang, N. et al. LYVE1+ macrophages of murine peritoneal mesothelium promote omentum-independent ovarian tumor growth. J. Exp. Med. 218, e20210924 (2021).
Lu, X. & Kang, Y. Chemokine (C–C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 284, 29087–29096 (2009).
Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222–225 (2011). This study shows that cancer cell-derived CCL2 recruits classical monocytes to the metastatic niche, thereby promoting breast cancer metastasis.
Martinez-Terroba, E. et al. Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment. Sci. Immunol. 9, eadh5462 (2024).
Ma, R. Y. et al. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J. Exp. Med. 217, e20191820 (2020).
LaMarche, N. M. et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 625, 166–174 (2024).
Hanna, R. N. et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C– monocytes. Nat. Immunol. 12, 778–785 (2011).
Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. Science 350, 985–990 (2015). This study provides genetic and functional evidence that NR4A1-expressing non-classical monocytes cooperate with NK cells to suppress lung cancer metastasis.
Narasimhan, P. B. et al. Patrolling monocytes control NK cell expression of activating and stimulatory receptors to curtail lung metastases. J. Immunol. 204, 192–198 (2020).
Kubo, H., Mensurado, S., Goncalves-Sousa, N., Serre, K. & Silva-Santos, B. Primary tumors limit metastasis formation through induction of IL15-mediated cross-talk between patrolling monocytes and NK cells. Cancer Immunol. Res. 5, 812–820 (2017).
Beffinger, M. et al. CSF1R-dependent myeloid cells are required for NK-mediated control of metastasis. JCI Insight 3, e97792 (2018).
Padgett, L. E. et al. Nonclassical monocytes potentiate anti-tumoral CD8+ T cell responses in the lungs. Front. Immunol. 14, 1101497 (2023).
Plebanek, M. P. et al. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche. Nat. Commun. 8, 1319 (2017).
Liu, X. et al. Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis. J. Clin. Invest. 134, e179527 (2024).
Wang, R. et al. Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27. J. Immunother. Cancer 10, e003539 (2022).
Mauvais, F. X. et al. Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors. Immunity 58, 843–860.e20 (2025).
Black, L. V. et al. The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles. Immunol. Cell Biol. 94, 430–438 (2016).
Matsumura, H. et al. Kupffer cells decrease metastasis of colon cancer cells to the liver in the early stage. Int. J. Oncol. 45, 2303–2310 (2014).
Deng, Z. et al. The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature 626, 864–873 (2024). This study shows that ID3-expressing Kupffer cells suppress liver metastasis by enhancing cancer cell engulfment.
Kimura, Y. et al. The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc. Natl Acad. Sci. USA 113, 14097–14102 (2016).
Li, J. et al. The ligation between ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis and antitumor immunity. Nat. Immunol. 24, 1813–1824 (2023).
Thomas, S. K. et al. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nat. Commun. 14, 6330 (2023).
Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015).
Pucci, F. et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352, 242–246 (2016).
Asano, K. et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34, 85–95 (2011).
Singh, R. & Choi, B. K. Siglec1-expressing subcapsular sinus macrophages provide soil for melanoma lymph node metastasis. eLife 8, e48916 (2019).
Xia, H. et al. Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight 5, e141115 (2020).
Chow, A. et al. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. Cancer Cell 39, 973–988.e9 (2021).
Rei, M. et al. Murine CD27–Vγ6+ γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, E3562–E3570 (2014).
Yin, M. et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J. Clin. Invest. 126, 4157–4173 (2016).
Song, M. et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat. Commun. 11, 6298 (2020).
Lebegge, E. et al. VSIG4-expressing macrophages contribute to antiparasitic and antimetastatic responses in the peritoneal cavity. Eur. J. Immunol. 55, e202551804 (2025).
Shi, C. et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 34, 590–601 (2011).
Flores-Toro, J. A. et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc. Natl Acad. Sci. USA 117, 1129–1138 (2020).
Tu, M. M. et al. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun. Biol. 3, 720 (2020).
Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651–662 (2016).
Nywening, T. M. et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67, 1112–1123 (2018).
Bonapace, L. et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130–133 (2014).
Halama, N. et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29, 587–601 (2016).
Cherney, R. J. et al. BMS-813160: a potent CCR2 and CCR5 dual antagonist selected as a clinical candidate. ACS Med. Chem. Lett. 12, 1753–1758 (2021).
O’Brien, S. A. et al. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunol. Immunother. 70, 2401–2410 (2021).
Pfirschke, C. et al. Macrophage-targeted therapy unlocks antitumoral cross-talk between IFNγ-secreting lymphocytes and IL12-producing dendritic cells. Cancer Immunol. Res. 10, 40–55 (2022).
DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623–637 (2014).
Salvagno, C. et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat. Cell Biol. 21, 511–521 (2019).
Maldonado, M. D. M., Schlom, J. & Hamilton, D. H. Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment. Cancer Immunol. Immunother. 72, 3349–3362 (2023).
Shimizu, D. et al. Pexidartinib and immune checkpoint inhibitors combine to activate tumor immunity in a murine colorectal cancer model by depleting M2 macrophages differentiated by cancer-associated fibroblasts. Int. J. Mol. Sci. 25, 7001 (2024).
Sato, T. et al. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages. JCI Insight 10, e178146 (2025).
Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264–1272 (2013).
Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).
Klemm, F. et al. Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. Nat. Cancer 2, 1086–1101 (2021).
Vacchelli, E. et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1, 894–907 (2012).
Rodell, C. B. et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578–588 (2018).
Bolli, E. et al. Targeted repolarization of tumor-associated macrophages via imidazoquinoline-linked nanobodies. Adv. Sci. 8, 2004574 (2021).
Sun, L. et al. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell 39, 1361–1374.e9 (2021). Together with Bolli et al. (2021), this work shows that PRR agonists (MPLA, a TLR4 agonist; and β-glucan, a dectin-1 agonist) synergize with IFNγ to enhance their antitumour functions.
Murphy, B. et al. Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer. J. Exp. Med. 221, e20231967 (2024).
Salomon, R. & Dahan, R. Next generation CD40 agonistic antibodies for cancer immunotherapy. Front. Immunol. 13, 940674 (2022).
Wiehagen, K. R. et al. Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunol. Res. 5, 1109–1121 (2017).
Hoves, S. et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J. Exp. Med. 215, 859–876 (2018).
Perry, C. J. et al. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J. Exp. Med. 215, 877–893 (2018).
Wattenberg, M. M. et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci. Immunol. 8, eadj5097 (2023).
Machiels, J. P. et al. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J. Immunother. Cancer 8, e001153 (2020).
Zhou, Y. et al. Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52, 357–373 e359 (2020).
Karikoski, M. et al. Clever-1/stabilin-1 controls cancer growth and metastasis. Clin. Cancer Res. 20, 6452–6464 (2014).
Viitala, M. et al. Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8+ T-cell response against immunosuppressive tumors. Clin. Cancer Res. 25, 3289–3303 (2019).
Rannikko, J. H. et al. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial. Cell Rep. Med. 4, 101307 (2023).
Rannikko, J. H., Bono, P., Hynninen, J. & Hollmen, M. Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments. Cancer Immunol. Res. 12, 48–59 (2024). This study provides the therapeutic insight that blocking stabilin-1 reprogrammes macrophages to an interferon-activated state.
Georgoudaki, A. M. et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15, 2000–2011 (2016).
Takahashi, H., Perez-Villarroel, P., Falahat, R. & Mule, J. J. Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming. J. Immunother. Cancer 13, e011030 (2025).
Masetti, M. et al. Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. J. Exp. Med. 219, e20210564 (2022).
Keshari, S. et al. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 43, 114875 (2024).
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900.e17 (2020).
Binnewies, M. et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37, 109844 (2021).
Di Luccia, B. et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci. Immunol. 9, eadi5374 (2024).
Yang, D. et al. TREM2 depletion in pancreatic cancer elicits pathogenic inflammation and accelerates tumor progression via enriching IL-1β+ macrophages. Gastroenterology 168, 1153–1169 (2025).
Zheng, J. et al. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro Oncol. 26, 811–825 (2024).
Son, J. et al. Inhibition of the CD47–SIRPα axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data. Front. Immunol. 13, 1027235 (2022).
Dooling, L. J. et al. Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses. Nat. Biomed. Eng. 7, 1081–1096 (2023).
Dooling, L. J. et al. Clustered macrophages cooperate to eliminate tumors via coordinated intrudopodia. Proc. Natl Acad. Sci. USA 122, e2425452122 (2025). Together with Dooling et al. (2023), this work show that antibody-dependent cellular phagocytosis in macrophages can be enhanced by inhibiting the ‘don’t eat me’ signal CD47–SIRPα and further boosted by activating IFNγ signalling.
Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76–84 (2018).
Zeller, T. et al. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. Front. Immunol. 13, 929339 (2022).
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).
Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P. & Ravetch, J. V. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 118, e2107424118 (2021).
Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med. 14, eabj1270 (2022).
Mei, Y. et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. Nat. Cancer 4, 1273–1291 (2023).
Gray, M. A. et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat. Chem. Biol. 16, 1376–1384 (2020).
Kaneda, M. M. et al. PI3Kγ is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539, 443–447 (2016). Together with Kaneda et al. (2016), this work shows that inhibiting PI3Kγ reprogrammes tumour-associated macrophages to an immunogenic state and reverses macrophage-driven resistance to immune checkpoint blockade, including anti-PD1 and anti-CTLA4 therapies.
Carnevalli, L. S. et al. Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3Kγ inhibition. Mol. Cancer Ther. 20, 1080–1091 (2021).
O’Connell, B. C. et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J. Immunother. Cancer 12, e009160 (2024).
Do, M. H. et al. Reprogramming tumor-associated macrophages to outcompete endovascular endothelial progenitor cells and suppress tumor neoangiogenesis. Immunity 56, 2555–2569 e2555 (2023).
Morrissey, M. A. et al. Chimeric antigen receptors that trigger phagocytosis. eLife 7, e36688 (2018).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171–1182 (2025).
Pierini, S. et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat. Commun. 16, 706 (2025).
Chen, S. et al. CAR macrophages with built-in CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nat. Commun. 16, 4069 (2025).
Wu, J. et al. Targeted glycan degradation potentiates cellular immunotherapy for solid tumors. Proc. Natl Acad. Sci. USA 120, e2300366120 (2023).
Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024).
Look, T. et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. Cell Rep. Med. 6, 101931 (2025).
Mishra, A. K. et al. Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing. Proc. Natl Acad. Sci. USA 120, e2310221120 (2023).
Wang, X. et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat. Commun. 14, 5778 (2023).
Jing, W. et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat. Cancer 6, 838–853 (2025). This study shows that in vivo delivery to macrophages of vectors encoding both a CAR and a chimeric bioactive molecule receptor (CBR), together with administration of the biomolecule (IL-2), achieves durable tumour control.
Kerzel, T. et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell 41, 1892–1910.e10 (2023).
Schwab, E. D. & Pienta, K. J. Cancer as a complex adaptive system. Med. Hypotheses 47, 235–241 (1996).
Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).
Janeway, C. A. Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13, 11–16 (1992).
Ansaldo, E., Farley, T. K. & Belkaid, Y. Control of immunity by the microbiota. Annu. Rev. Immunol. 39, 449–479 (2021).
Russell, T. et al. Oncogenesis as a selective force: adaptive evolution in the face of a transmissible cancer. Bioessays https://doi.org/10.1002/bies.201700146 (2018).